| Catalyst | Drug/Treatment | Stage | Probability of Approval | Description | Drug Type | Therapeutic Area | Source |
|---|---|---|---|---|---|---|---|
PDUFA 2026 | Phase 3 | -% | FDA review of the new drug application for the treatment of example condition. Read More | Small Molecule | Oncology | ||
PDUFA 2026 | Phase 3 | -% | FDA review of the new drug application for the treatment of example condition. Read More | Small Molecule | Oncology | ||
PDUFA 2026 | Phase 3 | -% | FDA review of the new drug application for the treatment of example condition. Read More | Small Molecule | Oncology |
Recent Updates
Recently added Catalysts
Orthofix Medical Inc.$11.63
+0.15 (+1.31%)
F 17Pipeline Score MedTech · Commercial
Market Cap
434.53 M
EPS
-1.50
P/E Ratio
-
Value Trade
6.56 M
SEC Financials
Q1 2026Dilution Risk
Revenue
196.71 M
R&D Expenses
15.32 M
Operating CF
-17.61 M
Total Assets
886.60 M
Total Liabilities
451.42 M
Equity
435.19 M
D/E Ratio
12,345
-11.67 %
Week
-11.3 %
1 Month
-21.76 %
3 Month
-24.83 %
6 Month
-73.94 %
5 Year
-6.52 %
All Time
Cash Data
Cash Position
120.28 M
Monthly Burn
5.87 M
Runway
18.5 mo
Burn Trend
SEC Filing
May 5, 2026
Overview
Volume
216.31 K
52 Week Range
9.50 - 16.99
% held by Insiders
1.12 %
% held by Institutions
90.88 %
Enterprise Value
575.92 M
Total Shares
39.60 M
Short %
6.19 %
Float Shares
38.21 M
Company Description
locked
Upcoming Catalyst
Drug Pipeline Intelligence
F17
Pipeline Score -
Pipeline ValueValuation Signal
0
Drugs Scored—
rNPV / MCap Top 15%
Micro Cap (rank 775 of 911)
Percentile RankOrthofix Medical Inc. has significant pipeline risk (17/100).
Clinical Trial Results
| Drug Name | Indications | Phase | Date | Trial Results Summary | Title | Source |
|---|---|---|---|---|---|---|
Example Drug | Example indication for clinical evaluation | Phase 3 | 2025-12-01 | The study met its primary endpoint demonstrating statistically significant improvement. Read More | Phase 3 Study Results Announcement | |
Example Drug | Example indication for clinical evaluation | Phase 3 | 2025-12-01 | The study met its primary endpoint demonstrating statistically significant improvement. Read More | Phase 3 Study Results Announcement | |
Example Drug | Example indication for clinical evaluation | Phase 3 | 2025-12-01 | The study met its primary endpoint demonstrating statistically significant improvement. Read More | Phase 3 Study Results Announcement |
Inside Trades
YEARLY INSIDER TRANSACTIONS
Sector Avg.
INSIDERS
SOLDINSIDERS
BOUGHT
SOLDINSIDERS
BOUGHT
POSITIVE SENTIMENT Based on 22 Insiders Transactions
Hedge Funds
Shares Held
HEDGE FUNDS
SOLDHEDGE FUNDS
BOUGHT
SOLDHEDGE FUNDS
BOUGHT
POSITIVE SENTIMENT Based on 27 hedge funds in the last quarter
18 buying (3 new)·9 selling (1 exited)·2 unchanged
Hedge Funds invested in OFIX
| HedgeFund Name ( 3 ) | % of Portfolio | Current MV - | Shares Owned - | Activity Avg Price $0 |
|---|---|---|---|---|
Example Capital Management | 2.5 % | 15.00 M | 250.00 K | |
Example Capital Management | 2.5 % | 15.00 M | 250.00 K | |
Example Capital Management | 2.5 % | 15.00 M | 250.00 K |
OFIX Institutional Ownership Trends
Current Insider %
5.20%
—+0.00%
Current Institutional %
62.40%
—+0.00%
Total Ownership
67.60%
Insider + Institutional
Data Points
1
1 Ticker(s)
Option Chain Statistics
| Expiration | Volume | Open Interest | Implied Volatility Calls | Implied Volatility Puts | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Calls | Puts | Put-Call Ratio | Calls | Puts | Put-Call Ratio | IV | OiWaIv | VWaIv | IV | OiWaIv | VWaIv | |
| 2026-07-17 | 0 | 0.00 | 0 | 0 | - | - | - | - | - | - | ||
| 2026-07-17 | 0 | 0.00 | 0 | 0 | - | - | - | - | - | - | ||
| 2026-07-17 | 0 | 0.00 | 0 | 0 | - | - | - | - | - | - | ||
Option Chain
| Calls | Strike | Puts | ||||
|---|---|---|---|---|---|---|
| Last Price | Volume | Open Interest | Last Price | Volume | Open Interest | |
| No data available | ||||||
Open interest
Today's Open Interest
1.00 M
Put-Call Ratio
1.1
Put Open Interest
480.00 K
Call Open Interest
520.00 K
Open Interest Avg (30-day)
900,000
Today vs Open Interest Avg (30-day)
11.11%
Option Volume
Today's Volume
750.00 K
Put-Call Ratio
0.95
Put Volume
360.00 K
Call Volume
390.00 K
Volume Avg (30-day)
800,000
Today vs Volume Avg (30-day)
-6.25%
Company News
OFIXStaged L4–L5 Anterior to Psoas (ATP) Approach with Posterior Instrumentation
A 54-year-old male with severe L4–L5 degenerative spondylolisthesis underwent a staged surgical procedure using an anterior to psoas approach followed by posterior instrumentation. The ATP instrumentation improved exposure and workflow during surgery. Postoperative imaging showed successful restoration of disc height and stable hardware positioning, with no complications reported.
Read more →OFIXFrom Nerve Pain to Full Recovery: Jason’s CervicalStim Device Experience
Jason faced severe cervical disc herniation, leading to nerve compression and loss of hand function. After undergoing cervical fusion surgery, he utilized the FDA-approved CervicalStim device to aid his recovery. With therapy and the device's support, Jason has regained full function and returned to his normal activities, sharing his positive experience to inspire others.
Read more →OFIXOrthofix Expands Pediatric Limb Reconstruction Portfolio with New FITBONE™ Innovation at POSNA 2026 Annual Meeting
Orthofix Medical Inc. has announced new innovations in pediatric limb reconstruction, aimed at enhancing treatment options for pediatric and small stature patients. These advancements will be showcased at the upcoming Pediatric Orthopedic Society of North America (POSNA) 2026 Annual Meeting in Orlando, Florida. The event is scheduled for May 6-8, 2026.
Read more →OFIXOrthofix Reports First Quarter 2026 Results Highlighting Steady Execution Following Spine Commercial Channel Actions; Reaffirms Full-Year 2026 Financial Guidance
Orthofix has reported its first quarter results for 2026, emphasizing steady execution in its operations, particularly following actions taken in the spine commercial channel. The company has reaffirmed its financial guidance for the full year of 2026, indicating confidence in its performance. Further details on the financial outcomes were not disclosed in the article.
Read more →OFIXOrthofix Reports First Quarter 2026 Results Highlighting Steady Execution Following Spine Commercial Channel Actions; Reaffirms Full-Year 2026 Financial Guidance LEWISVILLE, Texas —
Orthofix Medical Inc. reported its financial results for the first quarter of 2026, indicating steady execution following recent commercial channel actions. Net sales reached $196.7 million, with a reaffirmation of the full-year guidance amid expected improvements. The company showcased positive growth in various product categories, despite reporting a net loss of $(20.9) million. Challenges from distributor transitions and discontinued product lines were noted but are believed to be largely behind the company as it looks to strengthen operations throughout the year.
Read more →OFIXOrthofix to Report First Quarter 2026 Financial Results
Orthofix Medical Inc. will announce its first quarter 2026 financial results on May 5, 2026, before market opening. A conference call and webcast will follow at 8:30 am Eastern Time. Interested parties can join the call using the provided access numbers. The company emphasizes its dedication to improving patient outcomes through innovative medical technologies.
Read more →OFIXOrthofix Realigns Spine Leadership to Strengthen Focus and Execution
Orthofix Medical Inc. has announced a strategic realignment of its Spine leadership team to enhance decision-making and accelerate growth. The company reported preliminary net sales of approximately $196.7 million for Q1 2026, reflecting a modest increase compared to the previous year. The leadership changes are aimed at improving commercialization and operational synergies across its product portfolio.
Read more →OFIXOrthofix Realigns Spine Leadership to Strengthen Focus and Execution Company Reports Preliminary First Quarter 2026 Net Sales and Reaffirms 2026 Outlook LEWISVILLE, Texas —
Orthofix Medical Inc. has announced a strategic realignment of its Spine leadership team to enhance focus and execution in its core business. The company reported preliminary net sales of approximately $196.7 million for the first quarter of 2026, which marks a 1.6% increase over the previous year. Orthofix reaffirmed its full-year 2026 guidance, anticipating net sales between $850 million to $860 million. This growth strategy aims to leverage operational synergies and expand high-value opportunities in the Spine segment, while addressing changes in their leadership structure to facilitate faster decision-making.
Read more →OFIX▼ -6.2%on this news
Orthofix Reports Fourth Quarter and Full-Year 2025 Financial Results and Provides 2026 Financial Guidance
Orthofix Medical Inc. reported its financial results for Q4 and full-year 2025, showing a net sales increase and strong performance in key segments. The company provided optimistic guidance for 2026, focusing on expanding market penetration and enhancing commercial execution. Despite a reported net loss, adjusted EBITDA showed growth, indicating operational progress.
Read more →OFIX▼ -6.2%on this newsshared move
Orthofix Reports Fourth Quarter and Full-Year 2025 Financial Results and Provides 2026 Financial Guidance LEWISVILLE, Texas —
Orthofix Medical Inc. released its financial results for Q4 and the full year of 2025, reporting a net sales increase to $219.9 million. Despite facing a reported net loss of $(2.2) million in Q4, the company experienced growth across several key product categories, with significant contributions from Bone Growth Therapies and U.S. Limb Reconstruction. Looking ahead, Orthofix provided optimistic guidance for 2026, forecasting net sales between $850 million and $860 million, alongside a projected rise in adjusted EBITDA.
Read more →OFIXOrthofix to Participate in Upcoming Investor Conferences
Orthofix Medical Inc. has announced that its CEO Massimo Calafiore and CFO Julie Andrews will participate in upcoming investor conferences. This engagement aims to enhance visibility and provide updates on the company's advancements in medical technologies. Interested parties can access the presentations via the Orthofix Investor Relations website.
Read more →OFIXOrthofix to Report Fourth Quarter and Full-Year 2025 Financial Results
Orthofix Medical Inc. will announce its fourth quarter and full-year 2025 financial results on February 24, 2026. A conference call will be held at 8:30 am ET to discuss these results. Investors can access the call through provided phone numbers and a webcast. The company emphasizes its commitment to keeping investors informed through its website.
Read more →OFIX▼ -7.4%on this news
Orthofix Reports Third Quarter 2025 Financial Results LEWISVILLE, Texas —
Orthofix Medical Inc. reported its financial results for the third quarter of 2025, showcasing a notable increase in net sales despite a net loss. The company experienced a 5% rise in net sales compared to the previous year, driven primarily by growth in the U.S. Spine Fixation and Orthopedics segments. Additionally, Orthofix has narrowed its full-year sales guidance while raising the low end of its adjusted EBITDA guidance. Although the decision to discontinue the M6 product lines has introduced some challenges, the company has demonstrated solid operational performance and positive cash flow.
Read more →OFIX▲ +13.5%on this news
Orthofix Reports Second Quarter 2025 Financial Results LEWISVILLE, Texas —
Orthofix Medical Inc. reported its financial results for Q2 2025, indicating a 2.3% increase in net sales compared to the previous year. The company achieved positive adjusted EBITDA of $20.6 million and positive free cash flow of $4.5 million, despite a net loss of $14.1 million. Orthofix reaffirmed full-year guidance for net sales and adjusted EBITDA, while also highlighting challenges from the discontinued M6 product lines. New product launches are expected to enhance growth and patient outcomes moving forward.
Read more →OFIX▼ -10.9%on this news
Orthofix Reports First Quarter 2025 Financial Results LEWISVILLE, Texas —
Orthofix Medical Inc. has reported its financial results for Q1 2025, showing a year-over-year increase in net sales by 2.7% to $193.6 million. The company reaffirmed its full-year guidance for adjusted EBITDA and free cash flow, despite reporting a net loss of $(53.1) million. Key highlights include significant growth in the Bone Growth Therapies segment and the recent clearance of the TrueLok Elevate TBT System. While the company acknowledged some softness in specific segments due to optimization efforts, it expressed confidence in future growth based on strategic priorities.
Read more →OFIXForward-Looking Statements This news release may include forward-looking statements within the meaning of Section 21E of the Securities Exchange Act of 1934, as amended, and Section 27A of the Securities Act of 1933, as
Orthofix Medical Inc. announced the appointment of Vickie Capps to its Board of Directors, effective March 11, 2025. Capps brings significant experience in global business operations and corporate finance, which is deemed valuable at this pivotal stage in the company's strategic transformation. This change expands Orthofix's Board to ten members, comprising professionals with diverse backgrounds in healthcare and business. Capps expressed enthusiasm about contributing to the company's mission of delivering innovative medical technologies.
Read more →OFIXOrthofix Reports Fourth Quarter and Full-Year 2024 Results and Provides 2025 Financial Guidance Record Results Reflect Strong Execution as Company Focuses on Most Profitable Growth Opportunities in Spine, Or
Orthofix Medical Inc. reported strong financial results for the fourth quarter and full-year 2024, highlighting record net sales driven by growth in spine and orthopedic products. Despite a net loss of $(29.1) million in the fourth quarter, the company's adjusted EBITDA saw a significant increase, indicating improved operational efficiency. The company also announced its financial guidance for 2025, projecting net sales between $818 million and $826 million, factoring in the discontinuation of its M6 artificial disc lines to focus on more profitable areas. Overall, Orthofix enters 2025 with positive momentum and adjusted growth targets.
Read more →OFIXOrthofix Reports Third Quarter 2024 Results, Reiterates Full-Year 2024 Financial Guidance, and Introduces New Three-Year Financial Targets Building on Positive Momentum from Compelling Combination of Profita
Orthofix Medical Inc. reported its financial results for the third quarter of 2024, showing a 7% increase in net sales to $196.6 million compared to the previous year. The company maintained its guidance for full-year 2024 while introducing new three-year financial targets that reflect its commitment to sustained growth. Notable performance was seen in various segments, particularly U.S. Spine Fixation, which achieved an 18% increase in net sales. However, the company faced a net loss of $(27.4) million during the quarter.
Read more →OFIX▲ +19.5%on this news
Orthofix Reports Second Quarter 2024 Results and Raises Full-Year 2024 Financial Guidance LEWISVILLE, Texas —
Orthofix Medical Inc. reported a 6% increase in net sales for Q2 2024, totaling $198.6 million, and raised its full-year financial guidance. The company's Bone Growth Therapies saw a notable 12% growth, contributing to six consecutive quarters of double-digit increases. However, Orthofix incurred a net loss of $(33.4) million and reported negative earnings per share. The company anticipates achieving positive free cash flow for the second half of 2024.
Read more →OFIXOrthofix Reports First Quarter 2024 Results Recent Highlights • Net sales of $188.6 million, an increase of 7.7% on a reported basis and 7.5% on a constant currency basis over prior year • Bone Growth Thera
Orthofix Medical Inc. reported its first quarter 2024 financial results, showcasing net sales of $188.6 million, a 7.7% increase from the previous year. The company's Bone Growth Therapies and U.S. Spine Fixation segments exhibited robust growth, with increases of 10% and 16%, respectively. However, Orthofix also faced a net loss of $36 million for the quarter, though this represented an improvement over prior year losses. The company has raised its full-year sales guidance, reflecting positive market conditions and operational performance.
Read more →OFIXOrthofix Reports Fourth Quarter and Full Year 2023 Results Recent Highlights • Fourth quarter 2023 net sales of $200.4 million, an increase of 64% on a reported basis and 7% on a pro forma constant currency basis
Orthofix Medical Inc. reported strong financial results for the fourth quarter and full year of 2023, with net sales increasing significantly. The fourth quarter sales reached $200.4 million, reflecting a 64% increase year-over-year. Bone Growth Therapies demonstrated robust growth with a 15% sales rise. Despite these gains, the company faced a net loss of $22 million for the quarter, contributing to a full-year net loss of $151.4 million. Looking forward, the company provided guidance indicating an expected growth in net sales and adjusted EBITDA for 2024.
Read more →OFIXJulie Andrews Begins as New Chief Financial Officer at Orthofix LEWISVILLE, TEXAS —
Julie Andrews has officially begun her role as Chief Financial Officer at Orthofix Medical Inc. with a promising background in finance and executive leadership in the medical device sector. Previously, she served as CFO at Smart Wires Technology and held significant finance roles at Wright Medical Group and Medtronic. Her appointment reflects Orthofix's strategy to leverage experienced leadership to drive growth and improve operational performance. Andrews has received various stock-based incentives tied to company performance, underlining the company's commitment to aligning executive goals with shareholder interests.
Read more →OFIX▲ +9.8%on this news
Orthofix Medical Inc. Announces Preliminary 2023 Fourth Quarter and Full-Year Net Sales Results • Net sales of $200.3 million, an increase of 64% on a reported basis and an increase of 8% on a pro forma basis 
Orthofix Medical Inc. has reported preliminary net sales of approximately $200.3 million for the fourth quarter of 2023, representing a notable 64% increase year-over-year. Full-year net sales reached approximately $746.5 million, marking a 62% increase over 2022. Significant growth was noted across all business segments, with Bone Growth Therapies alone growing by 15% in Q4. The company expressed confidence in continuing this positive momentum into 2024 as they leverage opportunities in the market.
Read more →OFIXOrthofix Provides Executive Management Business Update and Appoints Julie Andrews as Chief Financial Officer • Massimo Calafiore begins as President and Chief Executive Officer, effective immediately
Orthofix Medical Inc. has announced significant changes in its executive management, with Massimo Calafiore appointed as President and Chief Executive Officer, effective immediately. Julie Andrews will take on the role of Chief Financial Officer starting January 15, 2024. Both executives bring a wealth of experience from their previous positions in the medical device industry. The company is optimistic about these appointments influencing its growth and strategic direction positively.
Read more →OFIXOrthofix Medical Inc. 3451 Plano Parkway Lewisville, TX 75056 USA Tel 214 937 2000 Orthofix.com News Release Orthofix Announces Agreement with Engine Capital and Appointment of Three New Independent Directors to Further
Orthofix Medical Inc. has announced the appointment of three new independent directors to its board, following a cooperation agreement with Engine Capital, a significant shareholder. This strategic move is aimed at enhancing the company's governance and advancing its position in the global spine and orthopedics market. The new directors bring extensive experience in finance, strategic development, and healthcare, contributing to Orthofix's focus on innovation and growth. Company leaders have expressed optimism about the potential for increased shareholder value and improved patient solutions.
Read more →OFIXOrthofix Medical Inc. 3451 Plano Parkway Lewisville, TX 75056 USA Tel 214 937 2000 Orthofix.com News Release Orthofix Names Massimo Calafiore as President and Chief Executive Officer Value-Building Medical Device Executi
Orthofix Medical Inc. has appointed Massimo Calafiore as the new President and CEO, effective in early 2024. Calafiore, currently CEO of LimaCorporate, brings extensive experience in the orthopedic and spine sectors. The Board believes his leadership will enhance the company's growth potential and drive shareholder value. Additionally, Interim CEO Catherine Burzik will not be seeking reelection to the Board in the upcoming annual meeting.
Read more →OFIXOrthofix Reports Third Quarter 2023 Results • In November 2023, entered into a new four-year financing agreement with borrowing capacity of up to $150 million • Net sales of $184.0 million, an increase of 6
Orthofix Medical Inc. reported its third-quarter financial results for 2023, showcasing significant growth in net sales, which reached $184 million, marking a 61% increase from the previous year. The company successfully established a new four-year financing agreement with a borrowing capacity of up to $150 million. Despite these positive developments, Orthofix reported a net loss of $28.9 million, which is larger than the loss recorded in the same quarter last year. Additionally, while growth was reported in key segments, the company experienced notable declines in international sales of spinal implants.
Read more →OFIXOrthofix Announces Leadership Changes 9/12/2023 Catherine Burzik Appointed Interim Chief Executive Officer Geoffrey Gillespie Appointed Interim Chief Financial Officer Puja Leekha Appointed Interim Chief Legal Officer LE
Orthofix Medical Inc. announced significant leadership changes, appointing Catherine Burzik as Interim CEO, Geoffrey Gillespie as Interim CFO, and Puja Leekha as Interim Chief Legal Officer. These appointments follow the termination of previous executives due to violations of the company's code of conduct, as determined by an independent investigation. The board emphasized that these matters do not impact the company's ongoing strategies or financial results. Burzik expressed confidence in the current management team to maintain operational continuity and support the company's commitments to stakeholders.
Read more →OFIXOrthofix Reports Second Quarter 2023 Results and Raises Revenue and Adjusted EBITDA Guidance • Net sales of $187.0 million, an increase of 58% on a reported basis and 7% on a pro forma constant currency basis over
Orthofix Medical Inc. reported a net sales increase of 58% for Q2 2023, reaching $187 million. The company highlighted significant growth in Bone Growth Therapies and U.S. spinal sales, driven by new products and distribution strategies. However, despite the rise in revenue, Orthofix experienced a net loss of $39.4 million, reflecting ongoing challenges in profitability. The company raised its revenue and adjusted EBITDA guidance for the full year 2023, indicating a positive outlook despite current financial hurdles.
Read more →OFIXOrthofix Medical Inc. 3451 Plano Parkway Lewisville, TX 75056 USA Tel 214 937 2000 Orthofix.com News Release Orthofix Announces Changes to Board of Directors LEWISVILLE, TEXAS —
Orthofix Medical Inc. has announced changes to its Board of Directors, re-appointing Catherine Burzik as Chair and re-electing Wayne Burris. Burzik previously served as the Chair of the Board from 2021-2022 and has extensive experience in the medical device industry. Burris will contribute his financial expertise as part of the Audit and Finance and Compliance and Ethics Committees. The newly formed Orthofix-SeaSpine organization aims to lead in spine and orthopedic solutions globally.
Read more →OFIXOrthofix Reports First Quarter 2023 Results • Net sales of $175.2 million, an increase of 65% on a reported basis and 12% on a pro forma constant currency basis over prior year • Bone Growth Therapies growt
Orthofix Medical Inc. (NASDAQ: OFIX) reported net sales of $175.2 million for Q1 2023, marking a 65% increase, and a 12% rise on a pro forma basis. The company achieved consistent growth across its product lines, particularly in bone growth therapies and spinal implants. Despite positive revenue growth, Orthofix reported a significant net loss of $60.9 million, a notable rise from the previous year's loss. The company is also launching new products aimed at the minimally invasive spine procedure market, looking to capture a $1.8 billion opportunity.
Read more →OFIXOrthofix Medical Reports Orthofix and SeaSpine Fourth Quarter and Full-Year 2022 Results LEWISVILLE, Texas —
Orthofix Medical announced its fourth-quarter and full-year 2022 financial results, along with the merger with SeaSpine that became effective on January 5, 2023. Orthofix reported a net sales decline of 2% for the quarter, though bone growth therapies grew by approximately 3%. In contrast, SeaSpine experienced a 14% net sales increase, fueled by strong demand in U.S. spinal implants and orthobiologics. Overall, both companies face challenges with net losses, but project optimistic sales figures for the first quarter of 2023.
Read more →OFIX▼ -6.6%on this news
Orthofix Medical Inc. Announces Preliminary SeaSpine and Orthofix 2022 Fourth Quarter and Full-Year Net Sales Results LEWISVILLE, Texas —
Orthofix Medical Inc. announced the preliminary net sales results for both SeaSpine and Orthofix for the fourth quarter and full year of 2022 following their merger, which became effective on January 5, 2023. SeaSpine reported a substantial increase in net sales while Orthofix saw a slight decline in its overall revenues, particularly in its Spinal Implants segment. The merger aims to leverage synergies from both companies to enhance growth and innovation in the spine and orthopedics sector. The combined entity is expected to lead improvements in patient treatment outcomes through advanced products and services.
Read more →OFIX▲ +6.6%on this newsshared move
Orthofix and SeaSpine Announce Completion of Merger of Equals to Create a Leading Global Spine and Orthopedics Company Orthofix and SeaSpine Stockholders Approve Merger Lewisville, Texas
Orthofix Medical Inc. and SeaSpine Holdings Corporation have completed their merger of equals, with stockholder approvals of 99% and 98%, respectively. The combined entity will operate under the Orthofix name and aims to establish itself as a leading global spine and orthopedics company with an extensive product portfolio. The merger will become effective from January 5, 2023, and the management team expresses optimism regarding growth and innovation opportunities. However, several risks related to integration and financial performance remain.
Read more →OFIXOrthofix and SeaSpine Announce John Bostjancic to Serve as CFO for Combined Company Post Closing Lewisville, Texas and Carlsbad, California
Orthofix and SeaSpine Announce John Bostjancic to Serve as CFO for Combined Company Post Closing Lewisville, Texas and Carlsbad, California November 18, 2022 Orthofix (NASDAQ: OFIX), a global medical device company with a spine and orthopedics focus, and SeaSpine (NASDAQ: SPNE)
Read more →OFIXOrthofix Reports Third Quarter 2022 Results • Net sales of $114.0 million, an increase of 1% on a reported basis and 5% on a constant currency basis over prior year • Global Orthopedics net sales growth of
Orthofix Reports Third Quarter 2022 Results -Net sales of $114.0 million, an increase of 1% on a reported basis and 5% on a constant currency basis over prior year -Global Orthopedics net sales growth of 19% on a constant currency basis driven by new product and channel investm
Read more →OFIX▼ -19.2%on this news
Orthofix and SeaSpine to Combine in Merger of Equals to Create Leading Global Spine and Orthopedics Company Highly complementary spine and orthopedics portfolios One of the industry s broadest biologics and regenerative
Orthofix and SeaSpine to Combine in Merger of Equals to Create Leading Global Spine and Orthopedics Company Lewisville, Texas and Carlsbad, California October 11, 2022 Orthofix (NASDAQ: OFIX), a global medical device company with a spine and orthopedics focus, and SeaSpine (NAS
Read more →OFIX▼ -19.2%on this news
Orthofix Announces Preliminary Third Quarter and Year-To-Date 2022 Net Sales Results Third quarter net sales of $114 million, an increase of 1% on a reported basis and 5% on a constant currency basis over prior year Glob
Orthofix Announces Preliminary Third Quarter and Year-To-Date 2022 Net Sales Results LEWISVILLE, Texas October 11, 2022 Orthofix Medical Inc. (NASDAQ:OFIX) today announced preliminary unaudited third quarter 2022 net sales of approximately $114 million, an increase of 1% on a r
Read more →OFIX▼ -7.8%on this news
Orthofix Reports Second Quarter 2022 Results • Net sales of $118.1 million, a decrease of 3% on a reported basis and flat on a constant currency basis over prior year • Global Orthopedics net sales growth o
Orthofix Reports Second Quarter 2022 Results -Net sales of $118.1 million, a decrease of 3% on a reported basis and flat on a constant currency basis over prior year -Global Orthopedics net sales growth of 11% on a constant currency basis driven by new products and channel inve
Read more →OFIX▼ -8.3%on this news
Orthofix Reports First Quarter 2022 Results • Net sales of $106.4 million, an increase of 1% on a reported basis and 2% on a constant currency basis over prior year • New product sales drive solid growth in
Orthofix Reports First Quarter 2022 Results -Net sales of $106.4 million, an increase of 1% on a reported basis and 2% on a constant currency basis over prior year -New product sales drive solid growth in Biologics, Spinal Implants, and Orthopedics -FDA grants PMA for AccelSti
Read more →OFIXOrthofix Medical Inc. 3451 Plano Parkway Lewisville, TX 75056 USA Tel 214 937 2000 Orthofix.com Orthofix Announces New Business Unit President Kimberley Elting, Chief Legal and Development Officer for Orthofix, Appointed
Orthofix Medical Inc. Lewisville, TX 75056 USA Orthofix Announces New Business Unit President Kimberley Elting, Chief Legal and Development Officer for Orthofix, Appointed to Lead Global Orthopedics Business LEWISVILLE, TEXAS April 8, 2022 Orthofix Medical Inc. (NASDAQ:OFIX),
Read more →OFIXOrthofix Reports Fourth Quarter and Fiscal Year 2021 Results Fourth quarter net sales of $125.1 million, an increase of 6% over the prior year 2021 annual net sales of $464.5 million, an increase of 14% over the prior ye
Orthofix Reports Fourth Quarter and Fiscal Year 2021 Results LEWISVILLE, Texas - February 25, 2022 - Orthofix Medical Inc. (NASDAQ:OFIX) today reported its financial results for the fourth quarter and fiscal year ended December 31, 2021. Net sales for the fourth quarter were $12
Read more →OFIX▲ +6.7%on this news
Orthofix Announces Preliminary 2021 Fourth Quarter and Full Year Net Sales Results Fourth quarter net sales of approximately $125 million, an increase of 11% sequentially and 6% versus the prior year 2021 annual net sale
Orthofix Announces Preliminary 2021 Fourth Quarter and Full Year Net Sales Results LEWISVILLE, Texas -January 10, 2022- Orthofix Medical Inc. (NASDAQ:OFIX) today announced preliminary unaudited fourth quarter 2021 net sales of approximately $125 million, an increase of 6% on a r
Read more →OFIXOrthofix Announces Appointment of Thomas A. West to Board of Directors LEWISVILLE, TEXAS
Orthofix Announces Appointment of Thomas A. West to Board of Directors LEWISVILLE, TEXAS - December 14, 2021 - Orthofix Medical Inc. (NASDAQ:OFIX), a global medical device company with a spine and orthopedics focus, today announced that Thomas A. West has been named to the Compa
Read more →OFIXOrthofix Reports Third Quarter 2021 Results Net sales of $112 million, an increase of 1.3% over the prior year period Double-digit growth over the prior year period for both global Spinal Implants and Orthopedics More th
Orthofix Reports Third Quarter 2021 Results LEWISVILLE, Texas - November 5, 2021- Orthofix Medical Inc. (NASDAQ:OFIX) today reported its financial results for the quarter ended September 30, 2021. Net sales were $112 million, earnings per share ("EPS") was $(0.11), and adjusted
Read more →OFIXOrthofix Provides Business Update LEWISVILLE, TEXAS
Orthofix Provides Business Update LEWISVILLE, TEXAS - September 29, 2021 - Orthofix Medical Inc. (NASDAQ:OFIX), a global medical device company with a spine and orthopedics focus, today provided a business update. The Company has experienced the impact of higher than expected vo
Read more →OFIXOrthofix Announces Appointment of Wayne Burris to Board of Directors LEWISVILLE, TEXAS
Orthofix Announces Appointment of Wayne Burris to Board of Directors LEWISVILLE, TEXAS - September 23, 2021 - Orthofix Medical Inc. (NASDAQ:OFIX), a global medical device company with a spine and orthopedics focus, today announced that Wayne C. Burris has been named to the Compa
Read more →OFIX▲ +6.8%on this news
Orthofix Reports Second Quarter 2021 Results Net sales of $121 million, up 66% compared to prior year and 5% compared to the second quarter of 2019 U.S. Spinal Implants net sales grew 56% compared to prior year and 37% o
Orthofix Reports Second Quarter 2021 Results LEWISVILLE, Texas - August 6, 2021- Orthofix Medical Inc. (NASDAQ:OFIX) today reported its financial results for the quarter ended June 30, 2021. Net sales were $121 million, earnings per share ("EPS") was $0.12, and adjusted EPS was
Read more →OFIXOrthofix Reports First Quarter 2021 Results Net sales of $106 million, up 1% compared to prior year, after a strong recovery in March U.S. Spinal Implants net sales grew 19% compared to prior year, as net sales increased
Orthofix Reports First Quarter 2021 Results LEWISVILLE, Texas - April 30, 2021- Orthofix Medical Inc. (NASDAQ:OFIX) today reported its financial results for the quarter ended March 31, 2021. Net sales were $105.6 million, earnings per share ("EPS") was $(0.30) and adjusted EPS w
Read more →OFIXOrthofix Announces Board Chair Transition Ron Matricaria to Conclude Service as Chairman of Orthofix Board of Directors Catherine Burzik to be Nominated for Election at the 2021 Annual Meeting LEWISVILLE, TEXAS
Orthofix Announces Board Chair Transition Ron Matricaria to Conclude Service as Chairman of Orthofix Board of Directors Catherine Burzik to be Nominated for Election at the 2021 Annual Meeting LEWISVILLE, TEXAS - April 7, 2021 - Orthofix Medical Inc. (NASDAQ:OFIX), a global me
Read more →OFIXOrthofix Reports Fourth Quarter and Fiscal Year 2020 Results Fourth quarter net sales of $117.6 million, within 3% of our 2019 results US Spine implant sales grew 11% compared to fourth quarter 2019, driven by record M6-
Orthofix Reports Fourth Quarter and Fiscal Year 2020 Results LEWISVILLE, Texas -February 26, 2021- Orthofix Medical Inc. (NASDAQ:OFIX) today reported its financial results for the fourth quarter and fiscal year ended December 31, 2020. Net sales for the fourth quarter were $117.
Read more →OFIXOrthofix Announces Preliminary 2020 Fourth Quarter and Full Year Net Sales Results Fourth quarter net sales of approximately $118 million, an increase of 6% sequentially and a decrease of 3% versus the prior year U.S. Sp
Orthofix Announces Preliminary 2020 Fourth Quarter and Full Year Net Sales Results LEWISVILLE, Texas -January 12, 2021- Orthofix Medical Inc. (NASDAQ:OFIX) today announced preliminary unaudited fourth quarter 2020 net sales of approximately $118 million, a decrease of 3% on a re
Read more →OFIXOrthofix Reports Third Quarter 2020 Results • Net sales of $111.0 million, an increase of 52% sequentially and within 2% of our 2019 performance • US Spinal Implants third quarter net sales increased 19% ov
Orthofix Reports Third Quarter 2020 Results LEWISVILLE, Texas -November 5, 2020- Orthofix Medical Inc. (NASDAQ:OFIX) today reported its financial results for the third quarter ended September 30, 2020. Net sales were $111.0 million, earnings per share ("EPS") was $0.24 and adjus
Read more →OFIXOrthofix and Neo Medical Announce Partnership to Develop and Market Single-Use Spinal Solutions Focused on Improving Patient Outcomes LEWISVILLE, TEXAS
Orthofix and Neo Medical Announce Partnership to Develop and Market Single-Use Spinal Solutions Focused on Improving Patient Outcomes LEWISVILLE, TEXAS - September 22, 2020 - Orthofix Medical Inc. (NASDAQ:OFIX), a global medical device company focused on musculoskeletal healing
Read more →OFIXPaul Gonsalves joins Orthofix as President of Global Extremities Business LEWISVILLE, TEXAS
Paul Gonsalves joins Orthofix as President of Global Extremities Business LEWISVILLE, TEXAS - September 14, 2020 - Orthofix Medical Inc. (NASDAQ:OFIX), a global medical device company focused on musculoskeletal products and therapies, today announced the appointment of Paul Gons
Read more →OFIXOrthofix Reports Second Quarter 2020 Results • Net sales of $73.1 million, a decrease of 37% compared to prior year on a reported and constant currency basis • Record Motion Preservation sales quarter of $3
Orthofix Reports Second Quarter 2020 Results LEWISVILLE, Texas - August 6, 2020 - Orthofix Medical Inc. (NASDAQ:OFIX) today reported its financial results for the second quarter ended June 30, 2020. Net sales were $73.1 million, earnings per share ("EPS") was ($0.96) and adjuste
Read more →OFIXOrthofix Announces Election of Jason Hannon to Board of Directors LEWISVILLE, TX.
Orthofix Announces Election of Jason Hannon to Board of Directors LEWISVILLE, TX. - June 8, 2020 - Orthofix Medical Inc., (NASDAQ:OFIX), a global medical device company focused on musculoskeletal products and therapies, today announced that Jason M. Hannon has been elected by it
Read more →OFIXOrthofix Reports First Quarter 2020 Results • Net sales of $104.8 million, a decrease of 3.9% compared to prior year and 3.4% on a constant currency basis • Cost management initiatives put in place to reduc
Orthofix Reports First Quarter 2020 Results LEWISVILLE, Texas - May 8, 2020 - Orthofix Medical Inc. (NASDAQ:OFIX) today reported its financial results for the first quarter ended March 31, 2020. Net sales were $104.8 million, diluted earnings per share ("EPS") was $1.32 and adju
Read more →OFIXOrthofix Announces Preliminary First Quarter 2020 Results and Provides Business Update LEWISVILLE, TX.
Orthofix Announces Preliminary First Quarter 2020 Results and Provides Business Update LEWISVILLE, TX. - April 9, 2020 - Orthofix Medical Inc. (NASDAQ:OFIX), a global medical device company focused on musculoskeletal healing products, today announced preliminary financial result
Read more →OFIXOrthofix Completes Acquisition of FITBONE Limb Lengthening System LEWISVILLE, TX.
Orthofix Completes Acquisition of FITBONE Limb Lengthening System LEWISVILLE, TX. - March 26, 2020 - Orthofix Medical Inc. (NASDAQ:OFIX), a global medical device company focused on musculoskeletal healing products, today announced it has completed the acquisition of assets assoc
Read more →OFIXOrthofix Reports Fourth Quarter and Fiscal Year 2019 Financial Results Fourth Quarter Highlights • Net sales of $121.5 million, an increase of 0.3% compared to prior year period and 0.9% on a constant currency bas
Orthofix Reports Fourth Quarter and Fiscal Year 2019 Financial Results Fourth Quarter Highlights Fiscal Year 2019 Highlights LEWISVILLE, Texas - February 24, 2020 - Orthofix Medical Inc. (NASDAQ:OFIX) today reported its financial results for the fourth quarter and fiscal year
Read more →OFIXOrthofix Announces Agreement to Acquire FITBONE Limb Lengthening System Transaction expands limb reconstruction portfolio LEWISVILLE, TX.
Orthofix Announces Agreement to Acquire FITBONE Limb Lengthening System Transaction expands limb reconstruction portfolio LEWISVILLE, TX. - February 4, 2020 - Orthofix Medical Inc. (NASDAQ:OFIX), a global medical device company focused on musculoskeletal healing products today
Read more →OFIXOrthofix Names Kevin Kenny President of Global Spine Business LEWISVILLE, TEXAS
Orthofix Names Kevin Kenny President of Global Spine Business LEWISVILLE, TEXAS - December 5, 2019 - Orthofix Medical Inc. (NASDAQ:OFIX), a global medical device company focused on musculoskeletal products and therapies, today announced the appointment of Kevin Kenny as Presiden
Read more →OFIXOrthofix Appoints Jon Serbousek as President and Chief Executive Officer Serbousek succeeds former President and CEO Brad Mason who previously announced his retirement LEWISVILLE, TEXAS
Orthofix Appoints Jon Serbousek as President and Chief Executive Officer Serbousek succeeds former President and CEO Brad Mason who previously announced his retirement LEWISVILLE, TEXAS - November 1, 2019 - Orthofix Medical Inc. (NASDAQ:OFIX), a global medical device company fo
Read more →OFIXOrthofix Reports Third Quarter 2019 Results • Jon Serbousek to succeed Brad Mason as President and Chief Executive Officer on
Orthofix Reports Third Quarter 2019 Results LEWISVILLE, Texas - October 28, 2019 - Orthofix Medical Inc. (NASDAQ:OFIX) today reported its financial results for the third quarter ended September 30, 2019. Net sales were $113.5 million, loss per share ("EPS") was ($2.14) and adjus
Read more →OFIXOrthofix Names Jon Serbousek to Succeed CEO - Serbousek to succeed Brad Mason upon his retirement on
Orthofix Names Jon Serbousek to Succeed CEO LEWISVILLE, TEXAS - August 5, 2019 - Orthofix Medical Inc. (NASDAQ:OFIX), a global medical device company focused on musculoskeletal products and therapies, today announced that it has named Jon Serbousek as President of its Global Spi
Read more →OFIXOrthofix Reports Second Quarter 2019 Results • Jon Serbousek to succeed Brad Mason as President and Chief Executive Officer on
Orthofix Reports Second Quarter 2019 Results LEWISVILLE, Texas - August 5, 2019 - Orthofix Medical Inc. (NASDAQ:OFIX) today reported its financial results for the second quarter ended June 30, 2019. Net sales were $115.9 million, loss per share ("EPS") was ($0.03) and adjusted E
Read more →OFIXOrthofix Reports First Quarter 2019 Results • Net sales of $109.1 million, an increase of 0.4% compared to prior year and 1.9% on a constant currency basis • Biologics products net sales increased 16.6% exc
Orthofix Reports First Quarter 2019 Results LEWISVILLE, Texas - May 6, 2019 - Orthofix Medical Inc. (NASDAQ:OFIX) today reported its financial results for the first quarter ended March 31, 2019. Net sales were $109.1 million, earnings per share ("EPS") was $0.05 and adjusted EPS
Read more →OFIXOrthofix Reports Fourth Quarter and Fiscal 2018 Financial Results, CEO Announces Plans to Retire Fourth Quarter Highlights • Net sales of $121.1 million, an increase of 3.6% compared to prior year and 4.4% on a co
Orthofix Reports Fourth Quarter and Fiscal 2018 Financial Results, CEO Announces Plans to Retire Fourth Quarter Highlights Fiscal Year 2018 Highlights LEWISVILLE, Texas - February 25, 2019 - Orthofix Medical Inc. (NASDAQ:OFIX) today reported its financial results for the fourt
Read more →OFIXOrthofix Medical Inc. 3451 Plano Parkway Lewisville, TX 75056 USA 214 937 2000 Orthofix.com News Release CONTACT: Mark Quick Denise Landry Investor Relations Media Relations Tel 214 937 2924 Tel 214 937 2529 markquick@or
Orthofix Medical Inc. 3451 Plano Parkway Lewisville, TX 75056 USA 214 937 2000 Orthofix.com News Release CONTACT: Mark Quick Denise Landry Investor Relations Media Relations Tel 214 937 2924 Tel 214 937 2529 markquick@orthofix.com deniselandry@orthofix.com O
Read more →OFIXOrthofix Announces Preliminary 2018 Fourth Quarter and Full Year Net Sales Results
Orthofix Announces Preliminary 2018 Fourth Quarter and Full Year Net Sales Results LEWISVILLE, Texas - January 8, 2019 - Orthofix Medical Inc. (NASDAQ:OFIX) today announced preliminary unaudited fourth quarter 2018 net sales of approximately $121 million. These preliminary resul
Read more →OFIXOrthofix Reports Third Quarter 2018 Financial Results Third Quarter Highlights • Net sales of $111.7 million, an increase of 6.1% compared to prior year or 6.6% on a constant currency basis • GAAP net loss
Orthofix Reports Third Quarter 2018 Financial Results Third Quarter Highlights LEWISVILLE, Texas - October 29, 2018 - Orthofix Medical Inc. (previously Orthofix International N.V.) (NASDAQ:OFIX) today reported its financial results for the third quarter ended September 30, 2018
Read more →OFIXOrthofix Reports Second Quarter 2018 Financial Results Second Quarter Highlights • Net sales of $111.5 million, an increase of 2.4% compared to prior year or 1.3% on a constant currency basis • Net income f
Orthofix Reports Second Quarter 2018 Financial Results Second Quarter Highlights LEWISVILLE, Texas - August 6, 2018 - Orthofix Medical Inc. (previously Orthofix International N.V.) (NASDAQ:OFIX) today reported its financial results for the second quarter ended June 30, 2018. Ne
Read more →OFIXOrthofix Reports First Quarter 2018 Financial Results Completes acquisition of Spinal Kinetics Highlights • Net sales of $108.7 million, an increase of 5.8% compared to prior year or 3.3% on a constant currency ba
Orthofix Reports First Quarter 2018 Financial Results Completes acquisition of Spinal Kinetics LEWISVILLE, Texas - April 30, 2018 - Orthofix International N.V. (NASDAQ:OFIX) today reported its financial results for the first quarter ended March 31, 2018. Net sales were $108.7 m
Read more →OFIXOrthofix, International N.V. 3451 Plano Parkway Lewisville, TX 75056 USA Tel 214 937 2000 Orthofix.com News Release CONTACT: Mark Quick Denise Landry Investor Relations Media Relations Tel 214 937 2924 Tel 214 937 2529 m
Orthofix, International N.V. 3451 Plano Parkway Lewisville, TX 75056 USA Tel 214 937 2000 Orthofix.com News Release CONTACT: Mark Quick Denise Landry Investor Relations Media Relations Tel 214 937 2924 Tel 214 937 2529 markquick@orthofix.com deniselandry@orthofi
Read more →OFIXOrthofix International Reports Fourth Quarter and Fiscal 2017 Financial Results Fourth Quarter Highlights • Net sales of $116.9 million, an increase of 7.7% compared to prior year and 6.1% on a constant currency b
Orthofix International Reports Fourth Quarter and Fiscal 2017 Financial Results Fourth Quarter Highlights Fiscal Year 2017 Highlights LEWISVILLE, Texas - February 26, 2018 - Orthofix International N.V. (NASDAQ:OFIX) today reported its financial results for the fourth quarter a
Read more →OFIXOrthofix Announces Preliminary 2017 Fourth Quarter and Full Year Net Sales Results Provides 2018 Net Sales Guidance
Orthofix Announces Preliminary 2017 Fourth Quarter and Full Year Net Sales Results Provides 2018 Net Sales Guidance LEWISVILLE, Texas - January 9, 2018 - Orthofix International N.V. (NASDAQ:OFIX), a global medical device company focused on musculoskeletal healing products and v
Read more →OFIXOrthofix International Reports Third Quarter 2017 Financial Results Third Quarter Highlights • Net sales of $105.2 million, an increase of 6.9% compared to prior year or 6.0% on a constant currency basis •
Orthofix International Reports Third Quarter 2017 Financial Results Third Quarter Highlights LEWISVILLE, Texas - October 30, 2017 - Orthofix International N.V. (NASDAQ:OFIX) today reported its financial results for the third quarter ended September 30, 2017. Net sales were $105
Read more →OFIXOrthofix International Reports Second Quarter 2017 Financial Results Second Quarter Highlights • Net sales of $108.9 million, an increase of 4.7% compared to prior year or 5.1% on a constant currency basis •
Orthofix International Reports Second Quarter 2017 Financial Results Second Quarter Highlights LEWISVILLE, Texas - August 7, 2017 - Orthofix International N.V. (NASDAQ:OFIX) today reported its financial results for the second quarter ended June 30, 2017. Net sales were $108.9 m
Read more →OFIXOrthofix International Reports First Quarter 2017 Financial Results First Quarter Highlights • Net sales of $102.7 million, an increase of 4.1% compared to prior year or 4.6% on a constant currency basis •
Orthofix International Reports First Quarter 2017 Financial Results First Quarter Highlights LEWISVILLE, Texas - May 4, 2017 - Orthofix International N.V. (NASDAQ:OFIX) today reported its financial results for the first quarter ended March 31, 2017. Net sales were $102.7 millio
Read more →OFIXOrthofix International Reports Fourth Quarter and Fiscal 2016 Financial Results Fourth Quarter Highlights • Net sales of $108.5 million, an increase of 3.7% compared to prior year and 4.2% on a constant currency b
Orthofix International Reports Fourth Quarter and Fiscal 2016 Financial Results Fourth Quarter Highlights Fiscal Year 2016 Highlights LEWISVILLE, Texas - February 27, 2017 - Orthofix International N.V. (NASDAQ:OFIX) today reported its financial results for the fourth quarter a
Read more →OFIXOrthofix Announces Preliminary 2016 Fourth Quarter and Full Year Net Sales Results Provides 2017 Net Sales Guidance
Orthofix Announces Preliminary 2016 Fourth Quarter and Full Year Net Sales Results Provides 2017 Net Sales Guidance LEWISVILLE, Texas - January 10, 2017 - Orthofix International N.V. (NASDAQ:OFIX), a diversified, global medical device company, today announced preliminary unaudi
Read more →OFIXOrthofix International Reports Third Quarter 2016 Financial Results • Net sales of $98.5 million, a decrease of 2.6% compared to prior year • GAAP net income from continuing operations of $10.4 million; an
Orthofix International Reports Third Quarter 2016 Financial Results LEWISVILLE, Texas - October 31, 2016 - Orthofix International N.V. (NASDAQ:OFIX) today reported its financial results for the third quarter ended September 30, 2016. For the third quarter of 2016, net sales were
Read more →OFIXOrthofix International Reports Second Quarter 2016 Financial Results Net sales of $104.1 million; an increase of 3.1% over prior year
Orthofix International Reports Second Quarter 2016 Financial Results Net sales of $104.1 million; an increase of 3.1% over prior year LEWISVILLE, Texas - August 1, 2016 - Orthofix International N.V. (NASDAQ:OFIX) today reported its financial results for the second quarter ended
Read more →OFIXOrthofix International Reports First Quarter 2016 Financial Results First Quarter Highlights Net sales of $98.7 million; an increase of 11.8% over prior year on a constant currency basis Adjusted EBITDA of $15.5 million,
Orthofix International Reports First Quarter 2016 Financial Results First Quarter Highlights LEWISVILLE, Texas - April 28, 2016 - Orthofix International N.V. (NASDAQ:OFIX) today reported its financial results for the first quarter ended March 31, 2016. For the first quarter of
Read more →OFIXOrthofix International Reports Fourth Quarter and Fiscal 2015 Financial Results Fourth Quarter Highlights Net sales of $104.6 million; an increase of 7.6% over prior year on a constant currency basis Adjusted EBITDA of $
Orthofix International Reports Fourth Quarter and Fiscal 2015 Financial Results Fourth Quarter Highlights Fiscal Year 2015 Highlights LEWISVILLE, Texas - February 29, 2016 - Orthofix International N.V. (NASDAQ:OFIX) today reported its financial results for the fourth quarter a
Read more →OFIXOrthofix Announces Preliminary Fourth Quarter 2015 and Full Year Net Sales Results
Orthofix Announces Preliminary Fourth Quarter 2015 and Full Year Net Sales Results LEWISVILLE, Texas - January 12, 2016 - Orthofix International N.V. (NASDAQ:OFIX), a diversified, global medical device company, today announced preliminary unaudited fourth quarter 2015 net sales
Read more →OFIXOrthofix International Reports Third Quarter 2015 Financial Results Third Quarter Highlights Third quarter net sales of $101.2 million; an increase of 4.1% over prior year on a constant currency basis Adjusted EBITDA of
Orthofix International Reports Third Quarter 2015 Third Quarter Highlights LEWISVILLE, Texas - November 3, 2015 - Orthofix International N.V. (NASDAQ:OFIX) today reported its financial results for the third quarter ended September 30, 2015, including net sales of $101.2 million
Read more →OFIXOrthofix International Reports Second Quarter 2015 Financial Results Second Quarter Highlights Second quarter reported net sales of $101.0 million; an increase of 5.0% on a constant currency basis Adjusted EBITDA of $17.
Orthofix International Reports Second Quarter 2015 Second Quarter Highlights LEWISVILLE, Texas - August 4, 2015 - Orthofix International N.V. (NASDAQ:OFIX) today reported its financial results for the second quarter ended June 30, 2015, including net sales of $101.0 million, di
Read more →OFIXOrthofix International Reports First Quarter 2015 Financial Results Lewisville, Texas
Orthofix International Reports First Quarter 2015 Lewisville, Texas - May 18, 2015 -- Orthofix International N.V. (NASDAQ:OFIX) (the "Company," "we," "us" or "our"), a diversified, global medical device company focused on developing and delivering innovative repair and regenerat
Read more →OFIXOrthofix International Reports Fourth Quarter and Fiscal 2014 Financial Results Appoints Doug Rice as Chief Financial Officer Lewisville, Texas
Orthofix International Reports Fourth Quarter and Fiscal 2014 Appoints Doug Rice as Chief Financial Officer Lewisville, Texas - April 29, 2015 -- Orthofix International N.V. (NASDAQ:OFIX) (the "Company," "we," "us" or "our"), a diversified, global medical device company focused
Read more →OFIXOrthofix International N.V. 3451 Plano Parkway Lewisville, TX 75056 USA Tel 214 937 2000 Orthofix.com News Release CONTACT: Mark Quick Denise Landry Investor Relations Media Relations Tel 214 937 2924 Tel 214 937 2529 ma
Mark Quick Denise Landry Investor Relations Media Relations Tel 214 937 2924 Tel 214 937 2529 markquick@orthofix.com deniselandry@orthofix.com Orthofix International Provides Update Regarding NASDAQ Listing Matters LEWISVILLE, TX. - March 24, 2015 - As previously di
Read more →OFIXOrthofix International N.V. 3451 Plano Parkway Lewisville, TX 75056 USA Tel 214 937 2000 Orthofix.com Orthofix International Announces Preliminary Net Sales Estimates for the 2014 and 2013 Fiscal Years and Updated Timing
Orthofix International Announces Preliminary Net Sales Estimates for the 2014 and 2013 Fiscal Years and Updated Timing Objectives for Completion of Amended and Late Filings LEWISVILLE, TX. January 12, 2015 Orthofix International N.V. (NASDAQ:OFIX) (the Company), a diversified,
Read more →OFIXOrthofix Provides Finance and Restatement Update Company Continuing to Finalize Audit Work Needed to Complete Restatement Filings Doug Rice to Become Interim CFO as Mark Heggestad Resigns Due to Personal Circumstances Co
Orthofix Provides Finance and Restatement Update Company Continuing to Finalize Audit Work Needed to Complete Restatement Filings Doug Rice to Become Interim CFO as Mark Heggestad Resigns Due to Personal Circumstances Conference Call to be Held on Thursday, September 25, 2014
Read more →OFIXOrthofix International N.V. 3451 Plano Parkway Lewisville, TX 75056 USA Tel 214 937 2000 Orthofix.com News Release CONTACT: Mark Quick Investor Relations Tel 214 937 2924 markquick@orthofix.com Orthofix Announces Appoint
markquick@orthofix.com Orthofix Announces Appointment of Luke T. Faulstick to Board of Directors Kathleen Regan to Retire from Board LEWISVILLE, TX. September 22, 2014 Orthofix International N.V., (NASDAQ:OFIX), a diversified, global medical device company focused on improvin
Read more →OFIXOrthofix Updates Filing Status Plans to Restate Prior Periods Financial Statements Company to Request NASDAQ Hearings Panel to Stay NASDAQ Delisting Credit Agreement Waiver Obtained
Orthofix Updates Filing Status Plans to Restate Prior Periods Financial Statements Company to Request NASDAQ Hearings Panel to Stay NASDAQ Delisting Credit Agreement Waiver Obtained LEWISVILLE, Texas, August 19, 2014 As previously disclosed, Orthofix International N.V. (NASDA
Read more →OFIXOrthofix, International N.V. 3451 Plano Parkway Lewisville, TX 75056 USA Tel 214 937 2000 Orthofix.com News Release CONTACT: Mark Quick Investor Relations Tel 214 937 2924 markquick@orthofix.com Orthofix Announces Delay
markquick@orthofix.com Orthofix Announces Delay of Form 10-Q Filing and Provides Preliminary Second Quarter 2014 Net Sales Results LEWISVILLE, Texas, August 6, 2014 Orthofix International N.V. (NASDAQ: OFIX) today announced that it is delaying the release of its financial res
Read more →OFIXOrthofix International N.V. 3451 Plano Parkway Lewisville, TX 75056 USA Tel 214 937 2000 Orthofix.com News Release CONTACT: Mark Quick Investor Relations Tel 214 937 2924 markquick@orthofix.com Orthofix International Rep
markquick@orthofix.com Orthofix International Reports First Quarter 2014 Results LEWISVILLE, TX. May 7, 2014 Orthofix International N.V. (NASDAQ:OFIX) today reported results for the first quarter ended March 31, 2014. Net sales were $101.3 million for the first quarter of 201
Read more →OFIXOrthofix, International N.V. News Release CONTACT: Mark Quick Investor Relations Tel 214 937 2924 markquick@orthofix.com 3451 Plano Parkway Lewisville, TX 75056 USA Tel 214 937 2000 Orthofix.com Mark A. Heggestad Joins O
Orthofix, International N.V. News Release CONTACT: Mark Quick Investor Relations Tel 214 937 2924 markquick@orthofix.com 3451 Plano Parkway Lewisville, TX 75056 USA Tel 214 937 2000 Orthofix.com Mark A. Heggestad Joins Orthofix as New Chief Financial Officer LEWISVILLE,
Read more →OFIXOrthofix, International N.V. 3451 Plano Parkway Lewisville, TX 75056 USA Tel 214 937 2000 Orthofix.com News Release CONTACT: Mark Quick Investor Relations Tel 214 937 2924 markquick@orthofix.com Orthofix Appoints James F
markquick@orthofix.com Orthofix Appoints James F. Hinrichs to its Board of Directors Mr. Hinrichs to Become Chair of Audit and Finance Committee LEWISVILLE, TX. April 25, 2014 Orthofix International N.V. (NASDAQ:OFIX) announced today that it has appointed James F. Hinrichs to
Read more →OFIXOrthofix, International N.V. 3451 Plano Parkway Lewisville, TX 75056 USA Tel 214 937 2000 Orthofix.com CONTACT: Mark Quick Investor Relations Tel 214 937 2924 markquick@orthofix.com Orthofix International Provides Fourth
markquick@orthofix.com Orthofix International Provides Fourth Quarter and Full-Year 2013 Results Announces Strategic Plan to Further Drive Profitable Growth Creates New Strategic Business Unit Structure to Enhance Focus and Provide Greater Transparency Company to Host Confer
Read more →OFIXOrthofix, International N.V. 3451 Plano Parkway Lewisville, TX 75056 USA Tel 214 937 2000 Orthofix.com News Release CONTACT: Mark Quick Investor Relations Tel 214 937 2924 markquick@orthofix.com Orthofix Announces Filing
markquick@orthofix.com Orthofix Announces Filing of Restated Financial Statements Restatement Set Forth in Amended Annual and Quarterly Reports Filed with SEC Company to Host Conference Call on Thursday, March 27 in Connection With Full-Year 2013 Results LEWISVILLE, Texas Mar
Read more →OFIXOrthofix Appoints Ronald A. Matricaria as New Chairman of the Board
Orthofix Appoints Ronald A. Matricaria as New Chairman of the Board LEWISVILLE, Texas March 20, 2014 Orthofix International N.V. (NASDAQ:OFIX) today announced the appointment of Ronald A. Matricaria as a Director and Chairman of the Board. Mr. Matricaria replaces Kathleen ( Kat
Read more →OFIXOrthofix Receives Expected NASDAQ Notice Intends to Request a Hearing Before NASDAQ Hearings Panel
Orthofix Receives Expected NASDAQ Notice Intends to Request a Hearing Before NASDAQ Hearings Panel LEWISVILLE, Texas February 12, 2014 Consistent with its press release of February 5, 2014, Orthofix International N.V. (NASDAQ:OFIX) ( Orthofix or the Company ) today confirmed t
Read more →OFIXOrthofix Provides Update on NASDAQ Listing Status Intends to Complete its Financial Restatement by End of First Quarter
Orthofix Provides Update on NASDAQ Listing Status Intends to Complete its Financial Restatement by End of First Quarter LEWISVILLE, Texas February 5, 2014 Orthofix International N.V. (NASDAQ:OFIX) ( Orthofix or the Company ) today provided an update on issues relating to its l
Read more →OFIXOrthofix Appoints Kathleen Regan as Interim Chair of the Board
Orthofix Appoints Kathleen Regan as Interim Chair of the Board LEWISVILLE, Texas January 23, 2014 Orthofix International N.V. (NASDAQ:OFIX) (the Company ) today announced that its Board of Directors (the Board ) has appointed Kathleen ( Kathy ) Regan, a director, as Interim Cha
Read more →OFIXOrthofix Appoints Dr. Anthony F. Martin to its Board of Directors
Orthofix Appoints Dr. Anthony F. Martin to its Board of Directors LEWISVILLE, Texas December 3, 2013 Orthofix International N.V. (NASDAQ:OFIX) (the Company) today announced the appointment of Anthony F. Martin, PhD to its Board of Directors, effective immediately. Dr. Martin ha
Read more →OFIXOrthofix Provides Update Regarding NASDAQ Listing Matters Lewisville, TX
Orthofix Provides Update Regarding NASDAQ Listing Matters Lewisville, TX, November 22, 2013 Orthofix International N.V. (NASDAQ:OFIX) (the Company ) today provided an update regarding the status of its compliance with the Listing Rules of the NASDAQ Stock Market ( NASDAQ ). As
Read more →OFIXOrthofix Appoints Two New Independent Board Members Randy Thurman Named Chairman; Expands Board to Eight Directors
Orthofix Appoints Two New Independent Board Members Randy Thurman Named Chairman; Expands Board to Eight Directors LEWISVILLE, Texas November 6, 2013 Orthofix International N.V. (NASDAQ:OFIX) (the Company) today announced the addition of Randy Thurman and Kathleen ( Kathy ) Re
Read more →OFIXOrthofix Receives Expected NASDAQ Notice Related to Late Filing of Form 10-Q Lewisville, TX
Orthofix Receives Expected NASDAQ Notice Related to Late Filing of Form 10-Q Lewisville, TX, August 19, 2013 Orthofix International N.V. (NASDAQ:OFIX) (the Company ) today announced that it received a notice from the NASDAQ Stock Market stating that the Company is no longer in
Read more →OFIXOrthofix Issues Financial Statement Non-Reliance Statement Company to Restate Financial Statements for Fiscal Years 2011 and 2012 and First Quarter 2013 Lewisville, TX
Orthofix Issues Financial Statement Non-Reliance Statement Company to Restate Financial Statements for Fiscal Years 2011 and 2012 and First Quarter 2013 Lewisville, TX, August 6, 2013 Orthofix International N.V. (NASDAQ:OFIX) (the Company ) today provided an update regarding th
Read more →OFIXOrthofix Postpones Second Quarter Earnings Release and Investor Conference Call Lewisville, TX
Orthofix Postpones Second Quarter Earnings Release and Investor Conference Call Lewisville, TX, July 29, 2013 Orthofix International N.V. (NASDAQ:OFIX) (the Company) today announced that it is postponing the release of its financial results for the second quarter 2013 and its
Read more →OFIXOrthofix Realigns Business Units to Support Future Growth Opportunities and Announces Leadership Changes Promotes Brad Niemann to President, BioStim Business Michael Finegan Appointed Chief Strategy Officer, and Jeff Sch
Orthofix Realigns Business Units to Support Future Growth Opportunities and Announces Leadership Changes Promotes Brad Niemann to President, BioStim Business Appointed Chief Strategy Officer, and Jeff Schumm Appointed Chief Administrative Officer; Mark Atkinson Named Chief L
Read more →OFIXOrthofix International Announces First Quarter 2013 Results Board of Directors Authorizes $50.0 million Share Repurchase Program Lewisville, TX
Orthofix International Announces First Quarter 2013 Results Lewisville, TX, May 8, 2013 Orthofix International N.V. (NASDAQ:OFIX) (the Company) today announced its results for the first quarter ended March 31, 2013. Net sales were $100.3 million, a 14% decrease over the first
Read more →OFIXOrthofix International Appoints Emily Buxton as Chief Financial Officer
Orthofix International Appoints Emily Buxton as Chief Financial Officer LEWISVILLE, Texas April 4, 2013 (BUSINESS WIRE) Orthofix International N.V., (NASDAQ:OFIX) (the Company) announced today that it has appointed Emily Buxton as its Chief Financial Officer. Ms. Buxton had bee
Read more →OFIXOrthofix International Appoints Brad Mason as President and Chief Executive Officer
Orthofix International Appoints Brad Mason as President and Chief Executive Officer LEWISVILLE, Texas March 13, 2013 (BUSINESS WIRE) Orthofix International N.V., (NASDAQ:OFIX) (the Company) announced today that it has appointed Brad Mason as its President and Chief Executive O
Read more →OFIXOrthofix International Announces 4th Quarter and Full Year 2012 Results Q4/12 gross profit margin of 83%, up 240 basis points Q4/12 reported operating margin of 22% and adjusted operating margin of 22%, up 80 basis point
Orthofix International Announces 4th Quarter and Full Year 2012 Results Lewisville, TX, February 21, 2013 Orthofix International N.V. (NASDAQ:OFIX) (the Company) today announced its results for the fourth quarter and year ended December 31, 2012. Net sales were $112.0 million
Read more →OFIXOrthofix International Provides Preliminary 2012 Results
Orthofix International Provides Preliminary 2012 Results LEWISVILLE, Texas January 7, 2013 (BUSINESS WIRE) Orthofix International N.V., (NASDAQ:OFIX) (the Company) provided today preliminary unaudited results for the fourth quarter, and year ending December 31, 2012. The Compan
Read more →OFIXOrthofix Concludes Bone Growth Stimulator Investigation
Orthofix Concludes Bone Growth Stimulator Investigation LEWISVILLE, Texas December 16, 2012 (BUSINESS WIRE) Orthofix International N.V., (NASDAQ:OFIX) (the Company) announced today that it has resolved all matters related to the investigation of its bone growth stimulation busi
Read more →OFIXOrthofix Executes Final Settlement Agreement Related to the Investigation of Blackstone Medical, Inc.
Orthofix Executes Final Settlement Agreement Related to the Investigation of Blackstone Medical, Inc. LEWISVILLE, Texas October 29, 2012 (BUSINESS WIRE) Orthofix International N.V., (NASDAQ:OFIX) (the Company) announced today that it has executed the final settlement agreement
Read more →OFIXOrthofix International Announces 3rd Quarter 2012 Results Reported Operating Margin of 19%; Adjusted Operating Margin of 21%, up 70 basis points Gross Profit Margin of 81%, up 80 basis points
Orthofix International Announces 3rd Quarter 2012 Results Lewisville, TX, October 24, 2012 Orthofix International N.V. (NASDAQ:OFIX) (the Company) today announced its results for the third quarter ended September 30, 2012. Net sales of $114.8 million represent a decrease of 2%
Read more →OFIXBrian McCollum to Lead Orthofix Spine Global Business Unit
Brian McCollum to Lead Orthofix Spine Global Business Unit LEWISVILLE, Texas October 16, 2012 (BUSINESS WIRE) Orthofix International N.V., (NASDAQ:OFIX) (the Company) announced today that it has promoted Brian McCollum to President of the Spine Global Business Unit. Mr. McCollu
Read more →OFIXOrthofix International Comments on Judge s Ruling
Orthofix International Comments on Judge s Ruling LEWISVILLE, Texas September 6, 2012 (BUSINESS WIRE) Orthofix International N.V., (NASDAQ:OFIX) (the Company) commented today on the federal court rejection of the previously signed plea agreement between the Department of Justice
Read more →OFIXOrthofix International Announces 2nd Quarter 2012 Results Net Sales were $119.5 million, up 2%; 5% constant currency; Reported and Adjusted Net Income from continuing operations up 33% and 11%, respectively Lewisville, T
Orthofix International Announces 2nd Quarter 2012 Results Net Sales were $119.5 million, up 2%; 5% constant currency; Reported and Adjusted Net Income from continuing operations up 33% and 11%, respectively Lewisville, TX, July 26, 2012 Orthofix International N.V. (NASDAQ:OFIX
Read more →OFIXIN THE UNITED STATES DISTRICT COURT FOR THE EASTERN DISTRICT OF TEXAS SHERMAN DIVISION SECURITIES AND EXCHANGE COMMISION, Plaintiff, vs. CIVIL ACTION NO.: ORTHOFIX INTERNATIONAL N.V., Defendant. CONSENT OF DEFENDANT ORTH
IN THE UNITED STATES DISTRICT COURT FOR THE EASTERN DISTRICT OF TEXAS SECURITIES AND EXCHANGE COMMISION, Plaintiff, vs. CIVIL ACTION NO.: ORTHOFIX INTERNATIONAL N.V., Defendant. CONSENT OF DEFENDANT ORTHOFIX INTERNATIONAL N.V. 1. Defendant Orthofix International N.V.
Read more →Competitive Position
How OFIX ranks across every disease it competes inCompetitive Position is a premium feature
See how OFIX ranks against every competitor across each disease it develops in: phase, best drug, trials and likelihood of approval.
Start free trial